Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie Spotlights Its Early-Stage R&D Pipeline

Executive Summary

A group of early-stage investigational cancer, myelofibrosis and immune-oncology products have been tagged by AbbVie as potential therapies of interest longer term.

 

Advertisement

Related Content

Cautious Restart To Venetoclax’s CANOVA Trial In Multiple Myeloma
AbbVie’s Humira Succession Plan Begins Taking Shape With Skyrizi US Approval
AbbVie Prices Oral Endometriosis Drug Orilissa In Value Range, Focusing On Access

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125151

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel